CEBPA and acute myeloid leukemia: Similarly, in a recent retrospective study in R/R-AML patients treated with venetoclax, NPM1 mutations was a significant predictor of response (with CR/CRi of 46%), and CEBPA mutations were also associated with higher CR/CRi [21].